<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AE58F21F-3622-4382-97BB-1359BD183E9F"><gtr:id>AE58F21F-3622-4382-97BB-1359BD183E9F</gtr:id><gtr:name>University of Glasgow</gtr:name><gtr:address><gtr:line1>University Avenue</gtr:line1><gtr:line4>Glasgow</gtr:line4><gtr:postCode>G12 8QQ</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/48C13E55-28C1-4AE4-BA67-521BE128FE74"><gtr:id>48C13E55-28C1-4AE4-BA67-521BE128FE74</gtr:id><gtr:firstName>Graeme</gtr:firstName><gtr:surname>Milligan</gtr:surname><gtr:orcidId>0000-0002-6946-3519</gtr:orcidId><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=BB%2FE019455%2F1"><gtr:id>9B21BAAC-B8D2-4663-A107-E212AAE99562</gtr:id><gtr:title>Uncovering the pharmacology of the G protein-coupled receptor GPR40</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>BB/E019455/1</gtr:grantReference><gtr:abstractText>G protein-coupled receptors (GPCRs) are both the largest family of transmembrane signalling proteins in man and the most successfully targetted as sites of action by therapeutically active small molecule medicines. Despite this, the ligands that activate many GPCRs remain either unknown or poorly characterised. Recently, the group of GPCRs named GPR40-GPR43 were shown to respond to medium- and long-chain fatty acids that circulate in the bloodstream. GPR40 is highly expressed by pancreatic beta-cells that produce and secrete insulin. It is known that, in the short term, elevation of blood fatty acid levels increase insulin secretion. However, in the longer term elevated blood fatty acids are detrimental to beta-cell function and it is known that the concentration of fatty acids is elevated in the blood of obese diabetics. At the moment, no GPCR targeted medicines are used to treat diabetes. However, we have recently shown that a group of clinically used medicines, called glitazones, activate GPR40 although their accepted mode of action is via activation of a completely different group of non-GPCR, nuclear receptors called Peroxisome Proliferator-Activated Receptors of the gamma subtype (PPARgamma). Although glitazones are used clinically they have side effects that limit their use and because they require to be used for significant amounts of time to produce benefits it is possible that at least some of their side effects reflect their ability to activate GPR40. Recently, models of how molecules related to medium-chain length fatty acids bind to their target GPCRs have been published. Comparing these models with the sequence of GPR40 has provided hypotheses on the molecular basis of how fatty acids interact with GPR40 and I will use combinations of mutagenesis and novel assays we have recently developed to measure activation of GPR40 to test these. I will also test if these mutations interfere with the activation of GPR40 by glitazones and by a group of small molecule chemicals also recently reported to activate GPR40. The major difference between fatty acids that activate GPR40 and those that active GPR41 and GPR43 is the length of the molecule. Comparisons of the sequences of GPR40 with GPR41 and GPR43 suggest key amino acids that may control this selectivity. This will also be tested by combinations of mutagenesis and functional assay. It can be hypothesised that a molecule that activates PPARgamma but inhibits GPR40 would be useful in the treatment of diabetes. I will thus also assess the activity of a range of other ligands that are related to the active glitazones but do not activate PPARgamma, for their ability to either activate or block activation of GPR40. Such mapping of the requirements for ligands to bind and to active GPR40 will provide new insights into how this GPCR is regulated and may, in the longer term help with further development of small molecules able to either activate or inhibit the function of this receptor.</gtr:abstractText><gtr:technicalSummary>GPR40, GPR41 and GPR43 are recently de-orphanised GPCRs. GPR40 responds to medium- and long-chain free fatty acids (FFAs) whilst both GPR41 and GPR43 respond to short-chain FFAs. Combinations of molecular modelling and mutagenesis have provided insights into the mechanism of binding of leukotriene B4 to its cognate GPCR BLT1. A key residue that acts to orientate leukotriene B4 between transmembrane helices 3 and 5 is an arginine near the top of helix 5. An equivalent arginine is present in each of GPR40, GPR41 and GPR43. Alteration of this arginine eliminates agonist function at GPR41 and GPR43 but has more modest effect in GPR40. A hypothesis to explain this is that the medium and long-chain FFAs extend substantially further down the gap between helices 3 and 5. Models of the binding of a synthetic GPR40 agonist to GPR40 suggest obvious residues that may contribute to the binding of FFAs. I hypothesise that mutation of a key residue in helix 5 will have greater effect on longer chain FFAs than those with shorter chains whilst mutation of the residue in helix 3 will have equal effects no matter FFA chain length because the helix 5 residue in deeper in the pocket. Comparisons between the sequences of GPR40 and both GPR41 and GPR43 suggest a patch of residues in helix 3 that may define chain length selectivity. This will be assessed. Particularly for GPR40 we have recently discovered that endogenous agonist ligand(s) become associated with the receptor during membrane preparation and removal of this ligand is required to 'uncover' the pharmacology of the receptor. Without this, the receptor appears, incorrectly, to be highly constitutively active. Key assays in this study will be based on this unique set of observations. Glitazones are anti-diabetic agents believed to target PPARgamma isoforms. However, they are also GPR40 agonists. Sustained activation of GPR40 is detrimental to beta cell function and I will thus also explore the SAR of GPR40/PPARgamma pharmacology.</gtr:technicalSummary><gtr:fund><gtr:end>2011-01-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/2512EF1C-401B-4222-9869-A770D4C5FAC7"><gtr:id>2512EF1C-401B-4222-9869-A770D4C5FAC7</gtr:id><gtr:name>BBSRC</gtr:name></gtr:funder><gtr:start>2008-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>360790</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs><gtr:impactSummaryOutput><gtr:description>They were central to my contributon to a large grant funded via the Danish Agency for Science, Technology and Innovation (2012-2016). 
FFARMED-The molecular effects of food on metabolic diseases through nutrient sensing free fatty acid receptors. 

This is turn has led to discussion on the potential to form a 'spin out;' company involving both University of Glasgow and University of Southern Denmark</gtr:description><gtr:firstYearOfImpact>2012</gtr:firstYearOfImpact><gtr:id>8A62E1E1-6C98-4DF8-A2FB-3FE6095F509D</gtr:id><gtr:impactTypes><gtr:impactType>Cultural,Economic</gtr:impactType></gtr:impactTypes><gtr:outcomeId>54579b253c6f62.30743935</gtr:outcomeId><gtr:sector>Agriculture, Food and Drink,Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:impactSummaryOutput></gtr:impactSummaryOutputs><gtr:intellectualPropertyOutputs/><gtr:keyFindingsOutput><gtr:description>These studies provided novel insights into how ligands bind to the receptor FFA1/GPR40. This receptor has become a key target in efforts to target new strategies for treatment of diabetes and it remains a key receptor being studies at a number of levels within my group</gtr:description><gtr:exploitationPathways>They have resulted in a number of applications for further support eg Danish Agency for Science, Technology and Innovation (2012-2016). FFARMED-The molecular effects of food on metabolic diseases through nutrient sensing free fatty acid receptors. &amp;pound;190,345 (100%) of GU. With Professor Trond Ulven, University of Southern Denmark. Total value 17,351,016 DKK
A substantial number of publications have flowed from this work including:
Watterson, K.R., Hudson, B.D., Ulven,, T., and Milligan, G. (2014) Treatment of type 2 diabetes by free fatty acid receptor agonists. Front Endocrinol (Lausanne).5:137.
Milligan, G., Alvarez-Curto, E., Watterson, K., Ulven, T. and Hudson B.D. (2014) Characterising pharmacological ligands to study the long chain fatty acid receptors GPR40/FFA1 and GPR120/FFA4. Br. J. Pharmacol. (in press).
Fjaere, E., Aune, U.L., Roen, K., Keenan, A.H., Ma, T., Borokowski, K., Kristensen, D.M., Novotny, G.W., Mandrup-Poulsen, T., Hudson, B.D., Milligan, G., Xi, Y., Newman, J.W., Haj, F.G., Liaset, B., Kristiansen, K.,and Madsen L. (2014) Indomethacin treatment prevents high fat diet-induced obesity and insulin resistance but not glucose intolerance in C57BL/6J mice. J. Biol. Chem. 289, 16032-16045
Hudson, B.D., Murdoch, H. and Milligan G (2013) The effects of species ortholog and SNP variation on receptors for free fatty acids. Mol. Endocrinol. 27, 1177-1187.
Christiansen, E., Hansen, S.V.F., Urban, C., Hudson, B.D., Wargent, E.T., Grundmann, M., Jenkins, L., Zaibi, M., Stocker, C.J., Ullrich, S., Kostenis, E., Kassack, M.U., Milligan, G., Cawthorne, M.A., and Ulven, T. (2013) Discovery of TUG-770: A highly potent Free Fatty Acid Receptor 1 (FFA1/GPR40) agonist for treatment of type 2 diabetes. ACS Med. Chem. Lett. 4, 441-445.
Christiansen, E, Due-Hansen, M.E., Urban, C., Grundmann, M., Schmidt, J., Hansen, S.V.F., Hudson, B.D., Zaibi, M., Markussen, S.B., Hagesaether, E., Milligan, G., Cawthorne, C.A., Kostenis, E., Kassack, M.U. and Ulven T. (2013) Discovery of a potent and selective FFA1 agonist with low lipophilicity and high oral bioavailability. J. Med. Chem. 56, 982-992.
Milligan, G., Ulven, T., Murdoch, H. and Hudson B.D. (2014) G protein-coupled receptors for free fatty acids: nutritional and therapeutic targets. Br. J. Nutrition 111, S3-S7.
Christiansen, E., Due-Hansen, M.E., Urban, C., Grundmann, M., Schroder, R., Hudson, B.D., Milligan, G., Cawthorne, M.A., Kostenis, E., Kassack, M.U. and Ulven, T. (2012) Free Fatty Acid Receptor 1 (FFA1/GPR40) agonists: Mesylpropoxy appendage lowers lipophilicity and improves ADME properties. J.Med.Chem. 55, 6624-6628.
Shimpukade B., Hudson, B.D., Hovgaaard C.K., Milligan, G. and Ulven, T. (2012) Discovery of a potent and selective GPR120 agonist. J. Med. Chem. 55, 4511-4515.</gtr:exploitationPathways><gtr:id>E7F190E9-F891-4065-ACE8-216EBAE6C003</gtr:id><gtr:outcomeId>54579a7707a128.20663028</gtr:outcomeId><gtr:sectors><gtr:sector>Pharmaceuticals and Medical Biotechnology</gtr:sector></gtr:sectors></gtr:keyFindingsOutput><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Caldan Therapeutics</gtr:companyName><gtr:description>Caldan Therapeutics Ltd is a spin out company based in Glasgow and established by myself and my academic co-founder Professor Trond Ulven of the University of Southern Denmark. The company is centred on the development of new therapeutics to treat type II diabetes by targeting the G protein-coupled receptors for long chain free fatty acids. Caldan Therapeutics recently raised &amp;pound;4.45Million of Series A funding to drive this venture.</gtr:description><gtr:id>AFD69B2E-3C51-4D81-93C5-28B10399441E</gtr:id><gtr:impact>None to date</gtr:impact><gtr:outcomeId>56b3156fbee479.40034478</gtr:outcomeId><gtr:yearCompanyFormed>2015</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>4E8981EE-D6F6-4AA3-BAF8-C70E9DE49A22</gtr:id><gtr:title>International Union of Pharmacology. LXXI. Free fatty acid receptors FFA1, -2, and -3: pharmacology and pathophysiological functions.</gtr:title><gtr:parentPublicationTitle>Pharmacological reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61a7eb773f07ea294985ca8ca932e6eb"><gtr:id>61a7eb773f07ea294985ca8ca932e6eb</gtr:id><gtr:otherNames>Stoddart LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0031-6997</gtr:issn><gtr:outcomeId>5457973fa9eb19.03867669</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C026A877-1033-47A2-B9B5-15FC044295E0</gtr:id><gtr:title>The action and mode of binding of thiazolidinedione ligands at free fatty acid receptor 1.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/70e47eafd29e227b2f9ea6213208387b"><gtr:id>70e47eafd29e227b2f9ea6213208387b</gtr:id><gtr:otherNames>Smith NJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>54579596444590.27634885</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>800D3248-5D51-4A5B-8335-2224C4F9B505</gtr:id><gtr:title>Constitutive activity of GPR40/FFA1 intrinsic or assay dependent?</gtr:title><gtr:parentPublicationTitle>Methods in enzymology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61a7eb773f07ea294985ca8ca932e6eb"><gtr:id>61a7eb773f07ea294985ca8ca932e6eb</gtr:id><gtr:otherNames>Stoddart LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2010-01-01</gtr:date><gtr:isbn>9780123812988</gtr:isbn><gtr:issn>0076-6879</gtr:issn><gtr:outcomeId>doi_55f94a94abd3bc40</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>CB11867D-491F-44C5-BF90-219BA28B640C</gtr:id><gtr:title>Complex Pharmacology of Free Fatty Acid Receptors.</gtr:title><gtr:parentPublicationTitle>Chemical reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85edc80268ea9bd4f3ba733ee9f05be5"><gtr:id>85edc80268ea9bd4f3ba733ee9f05be5</gtr:id><gtr:otherNames>Milligan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-2665</gtr:issn><gtr:outcomeId>585d373e49cef1.41153530</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C42E4099-1715-4E8E-BCC7-FF1E0F30FE56</gtr:id><gtr:title>Experimental challenges to targeting poorly characterized GPCRs: uncovering the therapeutic potential for free fatty acid receptors.</gtr:title><gtr:parentPublicationTitle>Advances in pharmacology (San Diego, Calif.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fafa3eb19a78acaea232fe40c8087fe6"><gtr:id>fafa3eb19a78acaea232fe40c8087fe6</gtr:id><gtr:otherNames>Hudson BD</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:isbn>9780123859525</gtr:isbn><gtr:issn>1054-3589</gtr:issn><gtr:outcomeId>5457963a1bfa73.03260572</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>EA5C900E-F60E-4D82-84C1-D31671FCE1F0</gtr:id><gtr:title>Conserved polar residues in transmembrane domains V, VI, and VII of free fatty acid receptor 2 and free fatty acid receptor 3 are required for the binding and function of short chain fatty acids.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/61a7eb773f07ea294985ca8ca932e6eb"><gtr:id>61a7eb773f07ea294985ca8ca932e6eb</gtr:id><gtr:otherNames>Stoddart LA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2008-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>doi_55f94a94abdc778d</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>51CB0586-A2BD-4703-BA4B-22F9AFAD8DB9</gtr:id><gtr:title>Agonism and allosterism: the pharmacology of the free fatty acid receptors FFA2 and FFA3.</gtr:title><gtr:parentPublicationTitle>British journal of pharmacology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/85edc80268ea9bd4f3ba733ee9f05be5"><gtr:id>85edc80268ea9bd4f3ba733ee9f05be5</gtr:id><gtr:otherNames>Milligan G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2009-01-01</gtr:date><gtr:issn>0007-1188</gtr:issn><gtr:outcomeId>doi_55f94a94abe6c340</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">BB/E019455/1</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>